This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

GAD 7 for screening for generalised anxiety disorder

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

GAD-7 Anxiety

Over the last 2 weeks, how often have you been bothered by the following problems?

Not at all

Several Days

More than half the days

Nearly every day

1. Feeling nervous, anxious or on edge

0

1

2

3

2. Not being able to stop or control worrying

0

1

2

3

3. Worrying too much about different things

0

1

2

3

4. Trouble relaxing

0

1

2

3

5. Being so restless that it is hard to sit still

0

1

2

3

6. Becoming easily annoyed or irritable

0

1

2

3

7. Feeling afraid as if something awful might happen

0

1

2

3

Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively

  • when used as a screening tool, further evaluation is recommended when the score is 10 or greater
  • study evidence revealed a cut point of 10 was identified that optimized sensitivity (89%) and specificity (82%) for diagnosis of generalised anxiety disorder

Limitations:

  • the GAD-7 scale focuses on only 1 anxiety disorder, although there are many patients with other anxiety disorders, such as social phobia and posttraumatic stress disorder, who need clinical attention
  • the GAD-7 provides only probable diagnoses that should be confirmed by further evaluation

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.